Updates on the Immune-related Oral Adverse Events

doi:10.12337/zgkqjxjyzz.2025.06.001

Chinese Journal of Stomatological Continuing Education ›› 2025, Vol. 28 ›› Issue (6): 377-383.DOI: 10.12337/zgkqjxjyzz.2025.06.001

Updates on the Immune-related Oral Adverse Events

Wenjin Tong^1,2, Rui Lu^1,2,*

¹State Key Laboratory of Oral & Maxillofacial Reconstruction and Regeneration, Key Laboratory of Oral Biomedicine Ministry of Education, Hubei Key Laboratory of Stomatology, School & Hospital of Stomatology, Wuhan University, Wuhan, Hubei Province, P.R.China;
²Department of Oral Medicine, School & Hospital of Stomatology, Wuhan University, Wuhan, Hubei Province, P.R.China

Online:2025-11-30 Published:2025-11-30
Contact: Rui Lu. Tel: 027-87686213. Email: lurui@whu.edu.cn. Address: Luoyu Road 237#, Wuhan 430079, Hubei Province, P.R.China.

Abstract

Abstract: As a novel anti-tumor therapeutic approach, immune-checkpoint inhibitors (ICIs) have significantly improved the prognosis of many patients with advanced malignancies. However, with increasing clinical application, immune-related adverse events (irAEs) induced by ICIs have become more frequent, involving various organ systems throughout the body and drawing extensive attention from clinical researchers. To date, studies and summaries focusing on oral irAEs remain relatively limited. This article summaries on the clinicopathological features and current management of oral irAEs, aiming to provide insights for clinical diagnosis, treatment and related research on such conditions.

Key words: immune-checkpoint inhibitors, immune-related adverse events, oral, clinicopathologic feature, disease management

Wenjin Tong, Rui Lu. Updates on the Immune-related Oral Adverse Events[J]. Chinese Journal of Stomatological Continuing Education, 2025, 28(6): 377-383.

References

[1] Bagchi S, Yuan R, Engleman EG.Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance[J]. Annu Rev Pathol, 2021, 16:223-249.
[2] De Velasco G, Je Y, Bossé D, et al.Comprehensive Meta-analysis of Key Immune-Related Adverse Events from CTLA-4 and PD-1/PD-L1 Inhibitors in Cancer Patients[J]. Cancer Immunol Res, 2017, 5(4):312-318.
[3] Xu Y, Wen N, Sonis ST, et al.Oral side effects of immune checkpoint inhibitor therapy (ICIT): An analysis of 4683 patients receiving ICIT for malignancies at Massachusetts General Hospital, Brigham & Women’s Hospital, and the Dana-Farber Cancer Institute, 2011 to 2019[J]. Cancer, 2021, 127(11):1796-1804.
[4] de Oliveira Filho OV, Gibbons IL, Medeiros YL, et al. Oral and cutaneous immune-related adverse events in cancer patients: Prevalence and overall survival[J]. Oral Dis, 2025, 31(1):278-285.
[5] Villa A, Schneider BJ, Lacchetti C, et al.Oral Immune-Related Adverse Events Secondary to Immune Checkpoint Inhibitors: Call to Action[J]. JCO Oncol Pract, 2025, 21(8):1073-1078.
[6] Elad S, Yarom N, Zadik Y, et al.The broadening scope of oral mucositis and oral ulcerative mucosal toxicities of anticancer therapies[J]. CA Cancer J Clin, 2022, 72(1):57-77.
[7] Jiang Q, Chen X, Wu J, et al.Oral Lichenoid lesions induced by programmed cell death protein 1 and cytotoxic T-lymphocyte-associated protein 4 bispecific antibody: a case report[J]. BMC Oral Health, 2024, 24(1):1240.
[8] Obara K, Masuzawa M, Amoh Y.Oral lichenoid reaction showing multiple ulcers associated with anti-programmed death cell receptor-1 treatment: A report of two cases and published work review[J]. J Dermatol, 2018, 45(5):587-591.
[9] Klein BA, Alves FA, de Santana RVJ, et al. Oral manifestations of immune-related adverse events in cancer patients treated with immune checkpoint inhibitors[J]. Oral Dis, 2022, 28(1):9-22.
[10] Bhattacharyya I, Chehal H, Migliorati C.Severe oral erosive lichenoid reaction to pembrolizumab therapy[J]. Oral Surg Oral Med Oral Pathol Oral Radiol, 2020, 130(5):e301-e307.
[11] Schaberg KB, Novoa RA, Wakelee HA, et al.Immunohistochemical analysis of lichenoid reactions in patients treated with anti-PD-L1 and anti-PD-1 therapy[J]. J Cutan Pathol, 2016, 43(4):339-346.
[12] Ramos-Casals M, Siso-Almirall A. Immune-Related Adverse Events of Immune Checkpoint Inhibitors[J]. Ann Intern Med, 2024, 177(2):ITC17-ITC32.
[13] Zhou G, Zhang J, Ren XW, et al.Increased B7-H1 expression on peripheral blood T cells in oral lichen planus correlated with disease severity[J]. J Clin Immunol, 2012, 32(4):794-801.
[14] Apalla Z, Nikolaou V, Fattore D, et al.European recommendations for management of immune checkpoint inhibitors-derived dermatologic adverse events. The EADV task force ‘Dermatology for cancer patients’ position statement[J]. J Eur Acad Dermatol Venereol, 2022, 36(3):332-350.
[15] Merli M, Accorinti M, Romagnuolo M, et al.Autoimmune bullous dermatoses in cancer patients treated by immunotherapy: a literature review and Italian multicentric experience[J]. Front Med (Lausanne), 2023, 10:1208418.
[16] Yun JSW, Chan OB, Goh M, et al.Bullous pemphigoid associated with anti-programmed cell death protein 1 and anti-programmed cell death ligand 1 therapy: A case series of 13 patients[J]. Australas J Dermatol, 2023, 64(1):131-137.
[17] Sowerby L, Dewan AK, Granter S, et al.Rituximab Treatment of Nivolumab-Induced Bullous Pemphigoid[J]. JAMA Dermatol, 2017, 153(6):603-605.
[18] Zumelzu C, Alexandre M, Le Roux C, et al.Mucous Membrane Pemphigoid, Bullous Pemphigoid, and Anti-programmed Death-1/Programmed Death-Ligand 1: A Case Report of an Elderly Woman With Mucous Membrane Pemphigoid Developing After Pembrolizumab Therapy for Metastatic Melanoma and Review of the Literature[J]. Front Med (Lausanne), 2018, 5:268.
[19] Sibaud V, Vigarios E, Siegfried A, et al.Nivolumab-related mucous membrane pemphigoid[J]. Eur J Cancer, 2019, 121:172-176.
[20] Shah KM, Rancour EA, Al-Omari A, et al. Striking enhancement at the site of radiation for nivolumab-induced Stevens-Johnson syndrome[J]. Dermatol Online J, 2018, 24(6):13030/qt97g3t63v.
[21] Yang F, Zhou P, Hua H.Severe oral and cutaneous immune-related adverse events induced by PD-1 inhibitors and antibody-drug conjugates: Case reports and management strategies[J]. Sci Prog, 2025, 108(3):368504251364109.
[22] Chwialkowska V, Slowinska M, Platkowska A, et al.Superficial mucoceles as a sequel to Stevens-Johnson syndrome during treatment of cutaneous squamous cell carcinoma with cemiplimab: A case report and review of literature[J]. Exp Ther Med, 2024, 29(1):15.
[23] Goldinger SM, Stieger P, Meier B, et al.Cytotoxic Cutaneous Adverse Drug Reactions during Anti-PD-1 Therapy[J]. Clin Cancer Res, 2016, 22(16):4023-4029.
[24] Shazib MA, Woo SB, Sroussi H, et al.Oral immune-related adverse events associated with PD-1 inhibitor therapy: A case series[J]. Oral Dis, 2020, 26(2):325-333.
[25] Shih T, Shih S, Sharaf M.Pembrolizumab-induced erythema multiforme requiring systemic immunosuppression[J]. Intern Med J, 2021, 51(12):2149-2150.
[26] Sundaresan S, Nguyen KT, Nelson KC, et al. Erythema multiforme major in a patient with metastatic melanoma treated with nivolumab[J]. Dermatol Online J, 2017, 23(9):13030/qt2513974h.
[27] Warner BM, Baer AN, Lipson EJ, et al.Sicca Syndrome Associated with Immune Checkpoint Inhibitor Therapy[J]. Oncologist, 2019, 24(9):1259-1269.
[28] Vigarios E, Epstein JB, Sibaud V.Oral mucosal changes induced by anticancer targeted therapies and immune checkpoint inhibitors[J]. Support Care Cancer, 2017, 25(5):1713-1739.
[29] Wang S, Sun J, Deng S, et al.Lichen planus pemphigoides induced by anti-PD-1 antibody: A case only involved in oral mucosa with excellent topical treatment efficiency[J]. J Cutan Pathol, 2024, 51(2):114-118.
[30] Jonna S, Neiders M, Lakshmanan S, et al.Linear IgA Disease of the Gingiva Following Nivolumab Therapy[J]. J Immunother, 2019, 42(9):345-347.
[31] Sonoda T, Waseda Y, Iino S, et al. The case of non-small cell lung cancer followed by lip lymphoproliferative disease after immunotherapy[J]. Ann Oncol, 2019, 30(Suppl 6):vi142.
[32] Chen Q, Li D, Zhang G, et al.An immune-related adverse event of Behcet’s-like syndrome following pembrolizumab treatment[J]. BMC Pulm Med, 2024, 24(1):166.
[33] Yu Q, Wang WX.Camrelizumab (SHR-1210) leading to reactive capillary hemangioma in the gingiva: A case report[J]. World J Clin Cases, 2020, 8(3):624-629.
[34] Yun SJ, Oh IJ, Park CK, et al.Vitiligo-like depigmentation after pembrolizumab treatment in patients with non-small cell lung cancer: a case report[J]. Transl Lung Cancer Res, 2020, 9(4):1585-1590.
[35] Shah N, Cohen L, Seminario-Vidal L.Management of oral reactions from immune checkpoint inhibitor therapy: A systematic review[J]. J Am Acad Dermatol, 2020, 83(5):1493-1498.
[36] Xu Y, Wen N, Haddad RI, et al.Comparisons of Non-Oral Immune-Related Adverse Events Among Patients with Cancer with Different Oral Toxicity Profiles[J]. Oncologist, 2024, 29(3):e382-e391.

Updates on the Immune-related Oral Adverse Events

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Qizhan Sun, Yufeng Wang. Research Status on T-cell Phenotypes and Immunopathological Heterogeneity in Oral Lichen Planus [J]. Chinese Journal of Stomatological Continuing Education, 2025, 28(6): 384-392.
[2]	Xiaoju Chen, Zhongfang Zhao, Xiaohan He, Bin Liu. Advances in Adhesive Drug Delivery for Recurrent Aphthous Ulcers [J]. Chinese Journal of Stomatological Continuing Education, 2025, 28(6): 393-397.
[3]	Yamin Tian, Yichen Li, Wei Ding. Compound Danshen Dropping Pills Combined with Compound Betamethasone in Treatment of Oral Submucous Fibrosis: A Case Report [J]. Chinese Journal of Stomatological Continuing Education, 2025, 28(6): 422-427.
[4]	Hongke Shi, Shuzhi Deng, Xueke Shi, Hongmei Zhou. Oral Lichenoid Lesions of Chronic Graft-Versus-Host Disease: A Case Report [J]. Chinese Journal of Stomatological Continuing Education, 2025, 28(6): 444-450.
[5]	Xinyi Dong, Min Li, Liu Wang, Shan Lu, Fangchun Chen. A Case of Oral Erythroleukoplakia Managed by Multidisciplinary Team [J]. Chinese Journal of Stomatological Continuing Education, 2025, 28(6): 451-459.
[6]	Ying Han, Zhimin Yan, Pan Wei, Hong Hua, Hongwei Liu. Exploration of The Application of A Hierarchical Progressive Training Model In Clinical Teaching of Oral Mucosal Diseases [J]. Chinese Journal of Stomatological Continuing Education, 2025, 28(6): 469-474.
[7]	Bingyue Xu, Han Lu, Keying Liu, Wei He. Advances in the Study of Microecological Dysbiosis in Medication-Related Osteonecrosis of the Jaw [J]. Chinese Journal of Stomatological Continuing Education, 2025, 28(5): 312-321.
[8]	Yingxu Na, Kun Qian. Current Application of Artificial Intelligence in Oral Medical Diagnosis Research [J]. Chinese Journal of Stomatological Continuing Education, 2025, 28(5): 337-344.
[9]	Dong Shi, Chenhao Yu, Yan Si, Zhongchen Song, Xiangying Ouyang, Yi Liu, Wenjie Hu, Yaping Pan. Current Status and Future Strategies of Periodontal Health Management in China [J]. Chinese Journal of Stomatological Continuing Education, 2025, 28(4): 189-193.
[10]	Danhui Xu, Jianfen Ding, Haiyan Lin, Kai Hu, Zixi Xin, Cuimei Liu, Hongping Zhu. Surveillance and Control of Hospital Acquired Infections in Inpatients of Oral and Maxillofacial Surgery Department [J]. Chinese Journal of Stomatological Continuing Education, 2025, 28(2): 76-82.
[11]	Chenhao Lv, Xiaoming Zhu, Yao Tan, Qing Chang, Deli Li, Jun Qian, Zhihui Tang, Jianguo Tan. Application of Facial-guided Oral Aesthetics Virtual Teaching in Dental Education [J]. Chinese Journal of Stomatological Continuing Education, 2025, 28(2): 83-88.
[12]	Liyong Jia, Qiong Chen, Yangyang Song. Effects of Remazolam Combined with Remifentanil on Oral Surgery [J]. Chinese Journal of Stomatological Continuing Education, 2025, 28(1): 12-17.
[13]	Di Wu, Zhanqiang Cao, Xiaofeng Zhao, Kun Qian, Jing Cui. Application of Mobile Intelligent Management System in the Management of Oral Reusable Instruments [J]. Chinese Journal of Stomatological Continuing Education, 2025, 28(1): 18-23.
[14]	Shuangtong Zhao, Hongyan Wang, Yaping Pan. Periodontal Management Strategy Based on European Federation of Periodontology S3 Level Clinical Practice Guideline for Periodontitis Treatment [J]. Chinese Journal of Stomatological Continuing Education, 2024, 27(4): 277-281.
[15]	RuiFang Li, Huan Liu, Lei Pan, Fei Pei. Discussion and Reform Proposals on Cultivating Scientific Research of Postgraduates Majoring in Periodontology [J]. Chinese Journal of Stomatological Continuing Education, 2024, 27(4): 364-368.